Itās not just smart science āĀ itās smart business and safer medicine.
ABK Biomedical, a company co-founded by Dr. Daniel Boyd, assistant professor in the Faculty of Dentistry, recently won the first ever BioInnovation Challenge for its OccluRad particles, which are used to treat fibroid tumours in women.
The BioInnovation Challenge is a competition designed by BioNova, Nova Scotiaās life sciences industry association, along with several other partners, seeking to create a smooth transition from lab to industry. The award went to Dr. Boyd and his co-investigators: Dr. Bob Abraham, an interventional radiologist, and Dr. Sharon Kehoe, a biomedical engineer and senior post-doctoral fellow in Dr. Boydās lab.
The winners were announced on September 28 at BioNova Atlantic 2011, BioNovaās annual life sciences conference.
Avoiding dyes
OccluRad is designed to treat a rather common medical condition: Dr. Boyd explains that 40 per cent of women over the age of 35 worldwide develop benign tumours in their uterus and many of them require a hysterectomy. To try and prevent this, clinicians have begun injecting tiny particles through the skin that impede blood flow to the tumour so it gradually reduces in size.
One problem with this, though, is that the particles canāt be seen in an X-ray, meaning that in order to see if the particles are working, physicians have to use a potentially toxic dye so they show up in the scans. In contrast, OccluRad particles are completely visible during X-rays, eliminating the need for toxic dyes. Ā
The finalists in the competition were judged based on their productsā innovation, perceived market pull and commercialization potential. The judges saw all three of these elements in OccluRad particles and awarded the prize to ABK Biomedical ā the company name Dr. Boyd is proposing be incorporated and have run out of Dal.
The $30,000 prize package includes $10,000 in seed funding and an advisory service package valued at $20,000. This includes legal consultation, mentoring and coaching, market evaluation and assessment, risk and insurance assessment, logistics, etc.
Supportive community
As you might expect, Dr. Boyd and his team are thrilled with their winnings.
āWe were blown away,ā explains Dr. Boyd. āItās very exciting simply because as a small company we need all the resources we can get our hands on. The prize package we received is providing us with services you canāt raise through grant money. Weāre delighted!ā
āWeāve gotten fantastic support from Dal, Springboard Atlantic, and Innovacorp,ā explains Dr. Boyd. āThe seed money will go towards the additional $500,000 weāre trying to raise to further demonstrate the safety and efficacy of our product.ā
The next steps for Dr. Boyd will be commercializing or āde-riskingā the product and making it a more viable product for doctors to use.
Despite its low profile, OccluRad particles are already a topic of conversation among clinicians who, once given a brief overview of the product, ask simply ā how quickly can we have it?